A Lack Of Efficacy In Vegf Inhibition For The Treatment Of Patients With Bladder Cancer

A lack of efficacy in VEGF inhibition for the treatment of patients with bladder cancer

Targeted Therapy for the Treatment of Advanced Metastatic Urothelial Cancer YouTube

Grand Rounds in Urology

Mechanisms of Angiogenesis Inhibitors in Metastatic Colorectal Cancer

New emerging treatment options and targeted therapies for bladder cancer

Beyond Checkpoint Inhibition: New Therapeutic Approaches to Bladder Cancer

Grand Rounds in Urology

Effect of FGFR status on checkpoint inhibitor response in bladder cancer

Erdafitinib demonstrates efficacy in intermediate-risk NMIBC with FGFR alterations

VEGF Inhibition in NSCLC

Erdafitinib and enfortumab vedotin in pretreated FGFR2/3-mutant bladder cancer

Combined inhibition of PARP and VEGF in gastric cancer

Webinar: First-in Human-Studies of FGFR Inhibitor KIN-3248 and RAF Inhibitor KIN-2787

Cholangiocarcinoma Foundation

FGFR-Specific TKIs Versus Multikinase Inhibitors

Targeted Oncology

Additional Insights: Experience with FGFR Inhibitors in Bladder Cancer

Targeted Oncology

Erdafitinib for bladder cancer: more to come following FDA approval

Case-Based Panel Discussion: Muscle-Invasive Bladder Cancer

Grand Rounds in Urology

The unmet needs of kidney cancer treatment

The Future of FGFR Inhibitor Treatment

Targeted Oncology

William Y. Kim, MD, a Damon Runyon Scientist

Damon Runyon Cancer Research Foundation

SPIRE trial: overcoming cisplatin resistance in bladder cancer with transcriptome changes

The role of erdafitinib in treating patients with bladder cancer